NESS ZIONA, Israel, January 12,
2017 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd.
(NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine
candidate M-001, reports the publication this week of an article
titled, "Back to the future: Immunization with M-001 prior to
trivalent influenza vaccine in 2011/12 enhanced protective immune
responses against 2014/15 epidemic strain" in the prestigious
peer-reviewed scientific journal Vaccine.
The Vaccine article reports that blood plasma samples
from people who received M-001 in 2011 (as part of BiondVax's
BVX-005 clinical trial in the elderly) showed significantly
increased protective antibodies against the new epidemic 2014/15
flu strain (A/Swiss) - a strain which did not exist when M-001 was
administered to the BVX-005 participants.
Despite the $4.3 billion
market[1], current flu vaccines have many shortcomings
including that they are specific to just 3 or 4 existing flu
strains, and must be reformulated each year. Furthermore, seasonal
flu vaccine effectiveness is only about 40% on
average[2], and as low as 9% in the
elderly[3] who are the most at risk group. Conversely,
as a universal flu vaccine candidate, M-001 is designed to provide
improved and broad protection against all current and future
seasonal and pandemic flu strains.
The study reported in Vaccine offers evidence of the
broadening protective effects offered by M-001, a significant
advantage over current flu vaccines.
Dr. Tamar Ben-Yedidia,
BiondVax's Chief Scientist and co-inventor of M-001, commented, "We
consider this study to provide validation of M-001's potential. It
is a promising indication that our vaccine may provide improved
protection against future flu strains, including potentially
pandemic strains that don't yet exist!"
The article also discusses M-001's mechanism of action. It is
available online at
http://www.sciencedirect.com/science/article/pii/S0264410X1631297X.
About BiondVax Pharmaceuticals Ltd
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend,"
"plan," "continue," "may," "will," "anticipate," and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve certain risks
and uncertainties reflect the management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include,
but are not limited to, the risk that drug development involves a
lengthy and expensive process with uncertain outcome,
general business conditions in the industry, changes in
regulatory and legal compliance environments in which BiondVax
engages, the adequacy of available cash resources to fund
product development and commercialization and the
ability to raise capital when needed. The risks, uncertainties and
assumptions referred to above are discussed in detail in our
reports filed with the Securities and Exchange Commission,
including our annual report for the year
ended December 31,
2015 on Form 20-F filed with the Securities and
Exchange Commission on April 27,
2016. BiondVax Pharmaceuticals Ltd. undertakes no obligation
to update or revise any forward-looking statements.
1. EvaluatePharma: Quoted by Edison Research
http://www.edisoninvestmentresearch.com/research/report/biondvax-pharmaceuticals/preview/
[accessed 12 January 2017].
2. CDC: Seasonal influenza vaccine effectiveness, 2005-2016.
https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm
[accessed 11 January 2017].
3. CDC: Interim adjusted estimates of seasonal influenza vaccine
effectiveness - United States,
February 2013. Available at:
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a2.htm [accessed
11 January 2017].
BiondVax is a clinical phase biopharmaceutical company
developing a universal flu vaccine. The vaccine is designed to
provide multi-season protection against most seasonal and pandemic
human influenza virus strains. BiondVax's proprietary technology
utilizes a unique combination of conserved and common peptides from
influenza virus proteins, activating both arms of the immune system
for a cross-protecting and long-lasting effect. BiondVax is traded
on NASDAQ: BVXV and TASE: BVXV. Please visit
http://www.biondvax.com.
For further information, please contact:
Joshua E Phillipson
Business Development
+972-8-930-2529 x5105
j.phillipson@biondvax.com
Kenny Green
Investor Relations
+1-646-201-9246
kenny@biondvax.com
SOURCE BiondVax Pharmaceuticals Ltd.